|
WO2021023238A1
|
|
Method for treating alzheimer's disease by inhibiting uptake of amino acids by t cells
|
|
WO2021023240A1
|
|
Method for identifying carbohydrate drug-sensitive patient in patients having alzheimer's disease
|
|
WO2021023237A1
|
|
Method for treating alzheimer's disease by regulating intestinal microorganisms
|
|
WO2021023241A1
|
|
Method for treating alzheimer's disease by regulating amino acid level
|
|
WO2021023239A1
|
|
Use of mannuronic acid oligosaccharides or composition comprising same in treatment of th1-dominance related diseases
|
|
CN110652523A
|
|
Application of composition of mannuronic aldehydic acid in treating vascular dementia
|
|
CN110652516A
|
|
Use of compositions of mannuronic acid for the treatment of parkinson's disease
|
|
CN110652524A
|
|
Use of compositions of mannuronic acid for the treatment of pain
|
|
CN110652525A
|
|
Use of compositions of mannuronic acid for the treatment of inflammation
|
|
CN110652517A
|
|
Algin oligosacchride diacid composition
|
|
CN110652526A
|
|
Application of composition of mannuronic acid in treating diabetes
|
|
CN110117333A
|
|
A kind of isolated sposknikovan and application thereof
|
|
CN110117331A
|
|
A kind of isolated Rhizoma imperatae polysaccharides and application thereof
|
|
CN110117332A
|
|
A kind of isolated sposknikovan and application thereof
|
|
CN110117330A
|
|
A kind of isolated Rhizoma imperatae polysaccharides and application thereof
|
|
US2020385417A1
|
|
Composition of mannuronic diacid
|
|
WO2018121581A1
|
|
Method of degrading polysaccharide using ozone
|
|
CN109459504A
|
|
A method of measurement guluronic acid sulfuric acid weight average molecular weight and content
|
|
CN109459503A
|
|
A method of measurement heparin class drug weight average molecular weight and content
|
|
CN109459523A
|
|
A method of measurement acid sugar soluble-salt weight average molecular weight and content
|
